Core Viewpoint - Plus Therapeutics, Inc. has announced a reverse stock split at a ratio of 1-for-25 to comply with Nasdaq's minimum bid price requirement of $1.00 for continued listing [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 12:01 a.m. Eastern Time on April 2, 2026, reducing the outstanding common stock from approximately 171,550,698 shares to about 6,862,027 shares [1][3]. - Every 25 shares of Plus Therapeutics common stock will be combined into one share, with no change to the par value of $0.001 per share [3]. - Holders of fractional shares will receive a cash payment instead of fractional shares, and the shares underlying the Company's outstanding equity awards and warrants will also be adjusted accordingly [3]. Group 2: Stockholder Instructions - The Company has retained Broadridge Financial Services, Inc. as the exchange agent for the reverse stock split, providing instructions for stockholders with shares in certificate form [4]. - Stockholders holding shares in book-entry form or brokerage accounts will see the impact of the reverse stock split reflected in their accounts without needing to take action [4]. Group 3: Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers, aiming to enhance clinical outcomes [5]. - The Company is advancing a pipeline of product candidates, particularly in leptomeningeal metastases and recurrent glioblastoma, supported by strategic partnerships for development and manufacturing [5].

Core Insights - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers [2] - The company will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025 [1] - Dr. Marc H. Hedrick, President and CEO of Plus Therapeutics, will engage in a fireside chat at the conference, available on demand for registered investors starting September 5 [2] Company Overview - Plus Therapeutics is headquartered in Houston, Texas, and specializes in targeted radiotherapeutics aimed at difficult-to-treat CNS cancers [2] - The company is advancing a pipeline of product candidates, with lead programs targeting leptomeningeal metastases and recurrent glioblastoma [2] - Plus Therapeutics has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [2]

Core Points - Plus Therapeutics, Inc. has confirmed compliance with Nasdaq Listing Rule 5550(b), meeting both the Market Value of Listing Securities (MVLS) standard of at least $35 million and the stockholders' equity threshold of at least $2.5 million [1][2] - Nasdaq has granted Plus Therapeutics an extension until November 12, 2025, to regain compliance with the $1.00 bid price rule, previously set for September 8, 2025 [2] - The company is under a one-year monitoring period for the Equity Standard, which will last until August 22, 2026, during which it must maintain compliance to avoid delisting [3] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for central nervous system cancers [4] - The company employs advanced technologies combining image-guided local beta radiation and targeted drug delivery, with key programs targeting leptomeningeal metastases and recurrent glioblastoma [4] - Plus Therapeutics has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [4]

Core Points - Plus Therapeutics, Inc. reported stockholders' equity of $3 million as of June 30, 2025, satisfying Nasdaq Listing Rule 5550(b)(1) [1][4] - The company was previously notified on June 3, 2025, that it no longer met the Equity Rule as of March 31, 2025, leading to a delist determination [2] - Following a hearing on July 15, 2025, the Nasdaq Hearings Panel granted an extension for the company to demonstrate compliance with the Equity Rule [3] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for central nervous system cancers [5] - The company utilizes image-guided local beta radiation and targeted drug delivery methods, with lead programs addressing leptomeningeal metastases and recurrent glioblastoma [5] - Plus Therapeutics has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [5]

Core Insights - Plus Therapeutics, Inc. is set to provide a business update on June 26, 2025, before the market opens, followed by a conference call and webcast at 9:00 a.m. ET [1] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for challenging central nervous system cancers [4] - The company aims to enhance clinical outcomes through a combination of image-guided local beta radiation and targeted drug delivery approaches [4] - Plus Therapeutics has a pipeline of product candidates, with lead programs targeting leptomeningeal metastases and recurrent glioblastoma [4] - The company has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [4]

Core Insights - Plus Therapeutics has announced a comprehensive restructuring of its previous $15 million equity financing, which eliminates the potential issuance of up to 1.5 billion shares of common stock, aiming to enhance shareholder value and simplify its equity capital structure [1][6]. Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for challenging central nervous system cancers, with a pipeline that includes programs for leptomeningeal metastases and recurrent glioblastoma [4]. Restructuring Details - The restructuring involves the cancellation of approximately 25 million shares of common stock or pre-funded warrants, which will further reduce stockholder dilution [6]. - The company has filed a request with the SEC to withdraw the resale registration statement related to the March 2025 equity financing [3]. - Future financing provisions state that 90% of proceeds from any capital raised after July 1, 2025, will be used to repay holders of 22,727,270 shares of common stock at 115% of the original price paid, based on an effective initial price of $0.66 per share [6].